AVEO - AVEO Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
2.93
-0.02 (-0.68%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.95
Open2.94
Bid2.50 x 100
Ask2.90 x 500
Day's Range2.84 - 2.96
52 Week Range0.50 - 4.24
Volume1,329,925
Avg. Volume2,401,435
Market Cap450.066M
Beta1.25
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • AVEO Pharmaceuticals, Inc. (AVEO) Continues to Build Strong Momentum in Its Oncology Programs
    SmarterAnalyst8 days ago

    AVEO Pharmaceuticals, Inc. (AVEO) Continues to Build Strong Momentum in Its Oncology Programs

    AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced updates on clinical development for FOTIVDA® (tivozanib), the Company’s potent, selective, long half-life inhibitor of all three vascular endothelial growth factor (VEGF) receptors, and ficlatuzumab, the Company’s humanized IgG1 antibody that binds to the hepatocyte growth factor (HGF) ligand with high affinity and specificity to inhibit the biological activities of the HGF/c-Met pathway. Enrollment Complete in Phase 2 Portion of Phase 1/2 TiNivo Trial in Advanced RCC. AVEO announced today that enrollment of 21 patients is now complete, with one patient remaining in screening, in the Phase 2 portion of the TiNivo study, a Phase 1/2 multicenter trial of tivozanib in combination with Bristol-Myers Squibb’s OPDIVO® (nivolumab), an immune checkpoint, or PD-1, inhibitor, for the treatment of advanced RCC.

  • AVEO Pharmaceuticals, Inc. (AVEO) Names New Senior Vice President of Regulatory and Quality Assurance
    SmarterAnalyst25 days ago

    AVEO Pharmaceuticals, Inc. (AVEO) Names New Senior Vice President of Regulatory and Quality Assurance

    AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) today expanded its executive team by naming Nikhil Mehta, Ph.D. as Senior Vice President of Regulatory and Quality Assurance, effective November 20, 2017. In this role, Dr. Mehta will oversee all aspects of regulatory, quality and technical operations for the company’s portfolio. Dr. Mehta brings to AVEO more than 25 years of experience in the biotechnology and pharmaceutical industries, having played a key role in the development and approval of important therapeutic products in the areas of oncology and orphan disease.

  • What’s Installed For AVEO Pharmaceuticals Inc (AVEO)?
    Simply Wall St.27 days ago

    What’s Installed For AVEO Pharmaceuticals Inc (AVEO)?

    AVEO Pharmaceuticals Inc (NASDAQ:AVEO), a USD$362.06M small-cap, is a healthcare company operating in an industry, which continues to be affected by the sustained economic uncertainty and structural trends, such asRead More...

  • Cancer Space Update: Label Expansion for Three Major Drugs
    Zacks28 days ago

    Cancer Space Update: Label Expansion for Three Major Drugs

    This week three major drugs received approval for label expansion in new indications. Moreover, a small biotech launched its first drug as a treatment for kidney cancer.

  • AVEO Pharmaceuticals Q3 Loss Narrows, Focus on Fotivda
    Zackslast month

    AVEO Pharmaceuticals Q3 Loss Narrows, Focus on Fotivda

    AVEO Pharmaceuticals reported narrower-than-expected adjusted loss in the third quarter. Moreover, it received approval for its first drug, Fotivda, which was approved in EU for bladder cancer.

  • Company Update (NASDAQ:AVEO): AVEO Pharmaceuticals, Inc. Provides 3Q:17 Update
    SmarterAnalystlast month

    Company Update (NASDAQ:AVEO): AVEO Pharmaceuticals, Inc. Provides 3Q:17 Update

    AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) reported financial results for the third quarter ended September 30, 2017 and provided a business update. Notably, with the European approval of tivozanib (FOTIVDA®) in advanced RCC, we have transitioned from a development stage company to one with a commercially approved product, a watershed achievement for any emerging life sciences company,” said Michael Bailey, president and chief executive officer of AVEO. “In addition, TIVO-3, our U.S. registration study, successfully passed the interim futility analysis with no changes to study protocol.

  • Associated Presslast month

    AVEO reports 3Q loss

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 22 cents. Losses, adjusted for non-recurring costs, came to 2 cents per share. The cancer drug company posted revenue ...

  • Why AVEO Pharmaceuticals, Inc. Tanked 18.6% in October
    Motley Foollast month

    Why AVEO Pharmaceuticals, Inc. Tanked 18.6% in October

    The wild ride continues.

  • AVEO Pharmaceuticals, Inc.’s (AVEO) and EUSA Pharma’s Tivozanib Combo Demonstrates Promise as a Potential Treatment for Advanced Renal Cell Carcinoma
    SmarterAnalystlast month

    AVEO Pharmaceuticals, Inc.’s (AVEO) and EUSA Pharma’s Tivozanib Combo Demonstrates Promise as a Potential Treatment for Advanced Renal Cell Carcinoma

    AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) and EUSA Pharma announced the presentation of promising results from the ongoing Phase 1 portion of the TiNivo study, a Phase 1/2 multicenter trial of tivozanib (FOTIVDA®) in combination with Bristol-Myers Squibb’s nivolumab (OPDIVO®), an immune checkpoint, or PD-1, inhibitor, for the treatment of advanced renal cell carcinoma (RCC). The results were presented on Friday, November 3, at the 16th International Kidney Cancer Symposium in Miami, in an oral presentation titled “TiNivo: A Phase Ib Dose Escalation Trial of Tivozanib and Nivolumab in Renal Cell Carcinoma” by Laurence Albiges, M.D., Ph.D., Head, Genitourinary Unit, Institute Gustave Roussy, and a lead investigator of the study.

  • Is AVEO Pharmaceuticals Poised for a Beat in Q3 Earnings?
    Zackslast month

    Is AVEO Pharmaceuticals Poised for a Beat in Q3 Earnings?

    AVEO Pharmaceuticals received approval for its first drug, Fotivda, as first-line treatment for RCC in Europe during the quarter. This is likely to have a favorable impact on third-quarter results.

  • Capital Cube2 months ago

    ETFs with exposure to AVEO Pharmaceuticals, Inc. : October 30, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to AVEO Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to AVEO-US. Comparing the performance and risk of AVEO Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • 3 Biotech Stocks That Turned $1,000 Into More Than $5,000 This Year
    Motley Fool2 months ago

    3 Biotech Stocks That Turned $1,000 Into More Than $5,000 This Year

    These three biotech stocks helped a lot of investors get rich this year. Are there more gains ahead?

  • Capital Cube2 months ago

    AVEO Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AVEO) : October 18, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives AVEO Pharmaceuticals, Inc. a score of 7. Our analysis is based on comparing AVEO Pharmaceuticals, Inc. with the following peers – Biogen Inc., Regeneron Pharmaceuticals, Inc., ArQule, Inc., GTx, Inc., Bristol-Myers Squibb Company, Merrimack Pharmaceuticals, Inc., Amgen Inc. and Eli Lilly and Company (BIIB-US, REGN-US, ARQL-US, GTXI-US, ... Read more (Read more...)

  • Here's Why AVEO Pharmaceuticals Dropped as Much as 16.3% Today
    Motley Fool2 months ago

    Here's Why AVEO Pharmaceuticals Dropped as Much as 16.3% Today

    Shares have seen increased volatility despite the company gaining its first-ever marketing approval recently.

  • AVEO Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AVEO-US : October 17, 2017
    Capital Cube2 months ago

    AVEO Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AVEO-US : October 17, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for AVEO Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)

  • Forbes2 months ago

    Two Techs And Two Biotechs Breaking Out

    Here are two biotech and two tech stocks that are breaking out technically.

  • MarketWatch2 months ago

    Harry Boxer’s four stocks that are breaking out this week

    In focus: Amicus Therapeutics, AVEO Pharmaceuticals, AXT and Dynavax Technologies.

  • Capital Cube3 months ago

    ETFs with exposure to AVEO Pharmaceuticals, Inc. : September 26, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to AVEO Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to AVEO-US. Comparing the performance and risk of AVEO Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Should You Have AVEO Pharmaceuticals Inc’s (AVEO) In Your Portfolio?
    Simply Wall St.3 months ago

    Should You Have AVEO Pharmaceuticals Inc’s (AVEO) In Your Portfolio?

    If you are a shareholder in AVEO Pharmaceuticals Inc’s (NASDAQ:AVEO), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...

  • Capital Cube3 months ago

    ETFs with exposure to AVEO Pharmaceuticals, Inc. : September 9, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to AVEO Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to AVEO-US. Comparing the performance and risk of AVEO Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube4 months ago

    ETFs with exposure to AVEO Pharmaceuticals, Inc. : August 25, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to AVEO Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to AVEO-US. Comparing the performance and risk of AVEO Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • AVEO Pharmaceuticals, Inc. :AVEO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017
    Capital Cube4 months ago

    AVEO Pharmaceuticals, Inc. :AVEO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017

    Categories: Yahoo FinanceGet free summary analysis AVEO Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of AVEO Pharmaceuticals, Inc. – Biogen Inc., Regeneron Pharmaceuticals, Inc., ArQule, Inc., Bristol-Myers Squibb Company, Amgen Inc., Eli Lilly and Company and Merrimack Pharmaceuticals, Inc. (BIIB-US, REGN-US, ARQL-US, BMY-US, ... Read more (Read more...)

  • AVEO Pharmaceuticals (AVEO) Q2 Loss Narrower than Expected
    Zacks4 months ago

    AVEO Pharmaceuticals (AVEO) Q2 Loss Narrower than Expected

    AVEO Pharmaceuticals (AVEO) reported narrower-than-expected adjusted loss in the second quarter. Its kidney cancer candidate, tivozanib is nearing approval in EU with positive CHMP recommendation.

  • Associated Press4 months ago

    AVEO reports 2Q loss

    The Cambridge, Massachusetts-based company said it had a loss of 30 cents per share. Losses, adjusted for non-recurring costs, came to 8 cents per share. The cancer drug company posted revenue of $351,000 ...